Table 2.
Worst grade hematologic toxicity by trial, for patients alive after period 1 (concomitant treatment) and after period 2 (maintenance treatment)
| During concomitant treatment | During maintenance temozolomide | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CENTRIC N = 504 N (%) |
CORE N = 242 N (%) |
EORTC 26082 N = 53 N (%) |
AVAglio N=882 N (%) |
EORTC 26981 N = 275 N (%) |
TOTAL N = 1956 N (%) |
CENTRIC N = 427 N (%) |
CORE N = 213 N (%) |
EORTC 26082 N = 39 N (%) |
AVAglio N = 761 N (%) |
EORTC 26981 N = 221 N (%) |
TOTAL N = 1661 N (%) |
|
| Neutropenia | ||||||||||||
| Any grade | 131 (26.0) | 70 (28.9) | 7 (13.2) | 109 (12.4) | 52 (18.9) | 369 (18.9) | 166 (38.9) | 54 (25.4) | 13 (33.3) | 218 (28.6) | 60 (27.1) | 511 (30.8) |
| Grade | ||||||||||||
| None | 365 (72.4) | 171 (70.7) | 46 (86.8) | 768 (87.1) | 215 (78.2) | 1565 (80.0) | 232 (54.3) | 141 (66.2) | 26 (66.7) | 511 (67.1) | 148 (67.0) | 1058 (63.7) |
| Grade 1–2 | 108 (21.4) | 60 (24.8) | 5 (9.4) | 72 (8.2) | 40 (14.5) | 285 (14.6) | 147 (34.4) | 50 (23.5) | 13 (33.3) | 180 (23.7) | 51 (23.1) | 441 (26.6) |
| Grade 3–4 | 23 (4.6) | 10 (4.1) | 2 (3.8) | 37 (4.2) | 12 (4.4) | 84 (4.3) | 19 (4.4) | 4 (1.9) | 0 (0.0) | 38 (5.0) | 9 (4.1) | 70 (4.2) |
| Missing | 8 (1.6) | 1 (0.4) | 0 (0.0) | 5 (0.6) | 8 (2.9) | 22 (1.1) | 29 (6.8) | 18 (8.5) | 0 (0.0) | 32 (4.2) | 13 (5.9) | 92 (5.5) |
| Thrombocytopenia | ||||||||||||
| Any grade | 164 (32.5) | 74 (30.6) | 5 (9.4) | 246 (27.9) | 30 (10.9) | 519 (26.5) | 185 (43.3) | 78 (36.6) | 5 (12.8) | 420 (55.2) | 59 (26.7) | 747 (45.0) |
| Grade | ||||||||||||
| None | 335 (66.5) | 167 (69.0) | 48 (90.6) | 632 (71.7) | 243 (88.4) | 1425 (72.9) | 216 (50.6) | 119 (55.9) | 34 (87.2) | 310 (40.7) | 156 (70.6) | 835 (50.3) |
| Grade 1–2 | 129 (25.6) | 64 (26.4) | 3 (5.7) | 206 (23.4) | 22 (8.0) | 424 (21.7) | 164 (38.4) | 71 (33.3) | 5 (12.8) | 362 (47.6) | 33 (14.9) | 635 (38.2) |
| Grade 3–4 | 35 (6.9) | 10 (4.1) | 2 (3.8) | 40 (4.5) | 8 (2.9) | 95 (4.9) | 21 (4.9) | 7 (3.3) | 0 (0.0) | 58 (7.6) | 26 (11.8) | 112 (6.7) |
| Missing | 5 (1.0) | 1 (0.4) | 0 (0.0) | 4 (0.5) | 2 (0.7) | 12 (0.6) | 26 (6.1) | 16 (7.5) | 0 (0.0) | 31 (4.1) | 6 (2.7) | 79 (4.8) |
| Anemia | ||||||||||||
| Any grade | 227 (45.0) | 104 (43.0) | 29 (54.7) | 338 (38.3) | 177 (64.4) | 875 (44.7) | 169 (39.6) | 70 (32.9) | 19 (48.7) | 302 (39.7) | 130 (58.8) | 690 (41.5) |
| Grade | ||||||||||||
| None | 272 (54.0) | 137 (56.6) | 24 (45.3) | 540 (61.2) | 96 (34.9) | 1069 (54.7) | 232 (54.3) | 127 (59.6) | 20 (51.3) | 428 (56.2) | 85 (38.5) | 892 (53.7) |
| Grade 1–2 | 223 (44.2) | 104 (43.0) | 29 (54.7) | 332 (37.6) | 176 (64.0) | 864 (44.2) | 169 (39.6) | 70 (32.9) | 19 (48.7) | 299 (39.3) | 128 (57.9) | 685 (41.2) |
| Grade 3–4 | 4 (0.8) | 0 (0.0) | 0 (0.0) | 6 (0.7) | 1 (0.4) | 11 (0.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 3 (0.4) | 2 (0.9) | 5 (0.3) |
| Missing | 5 (1.0) | 1 (0.4) | 0 (0.0) | 4 (0.5) | 2 (0.7) | 12 (0.6) | 26 (6.1) | 16 (7.5) | 0 (0.0) | 31 (4.1) | 6 (2.7) | 79 (4.8) |
| Lymphopenia * | ||||||||||||
| Any grade | 412 (81.7) | 198 (81.8) | 39 (73.6) | – | – | 649 (81.2) | 354 (82.9) | 161 (75.6) | 28 (71.8) | – | – | 543 (80.0) |
| Grade | ||||||||||||
| None | 84 (16.7) | 43 (17.8) | 14 (26.4) | – | – | 141 (17.6) | 44 (10.3) | 34 (16.0) | 11 (28.2) | – | – | 89 (13.1) |
| Grade 1–2 | 289 (57.3) | 144 (59.5) | 31 (58.5) | – | – | 464 (58.1) | 247 (57.8) | 125 (58.7) | 17 (43.6) | – | – | 389 (57.3) |
| Grade 3–4 | 123 (24.4) | 54 (22.3) | 8 (15.1) | – | – | 185 (23.2) | 107 (25.1) | 36 (16.9) | 11 (28.2) | – | – | 154 (22.7) |
| missing | 8 (1.6) | 1 (0.4) | 0 (0.0) | –– | – | 9 (1.1) | 29 (6.8) | 18 (8.5) | 0 (0.0) | – | – | 47 (6.9) |
*Lymphocyte counts were not available in AVAglio and EORTC 26082